DiscoveryProbe™ FDA-approved Drug Library: Gold Standard for High-Throughput Screening & Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) by APExBIO consists of 2,320 bioactive compounds approved by major regulatory agencies, packaged in 10 mM DMSO solutions for direct use in high-throughput and high-content screening (APExBIO product page). This library enables systematic drug repositioning, target identification, and mechanistic studies due to its comprehensive mechanism-of-action coverage (RG-108 article). Benchmark studies have demonstrated its reproducibility and broad disease applicability, especially in oncology and neurodegenerative research (Amyloid-A article). The compounds remain stable for 12–24 months when stored at recommended temperatures, ensuring reliable results. The library is cited in peer-reviewed studies for ligand screening, such as the direct binding of eltrombopag to syndecan-4 in cancer models (Am J Cancer Res 2022).

Biological Rationale

The identification of novel therapeutic targets and the repurposing of approved drugs are strategic priorities in translational research. The DiscoveryProbe™ FDA-approved Drug Library leverages compounds with established clinical safety and efficacy. These compounds modulate diverse targets, including G-protein-coupled receptors, enzymes, ion channels, and signaling proteins, reflecting the mechanistic heterogeneity of human disease (APExBIO). The library's design aligns with precision medicine and drug repositioning paradigms, enabling systematic screening for new indications and mechanistic insights. Representative compounds, such as doxorubicin, metformin, and atorvastatin, are included to support oncology, metabolic, and cardiovascular research. Regulatory coverage from FDA, EMA, HMA, CFDA, and PMDA ensures global translational relevance.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library comprises compounds with well-characterized pharmacological profiles. These include:

• Receptor agonists/antagonists: e.g., eltrombopag (TPOR agonist), propranolol (β-adrenergic antagonist).
• Enzyme inhibitors: e.g., atorvastatin (HMG-CoA reductase inhibitor), metformin (AMPK activator, indirect mitochondrial complex I inhibitor).
• Ion channel modulators: e.g., amlodipine (calcium channel blocker).
• Signal pathway regulators: e.g., drugs modulating MAPK and PI3K/AKT pathways.

Each compound's inclusion is based on documented mechanism-of-action and clinical approval status (see curated summary). Eltrombopag, for example, was shown to bind syndecan-4 and enhance MAPK signaling and macropinocytosis in cancer cells, illustrating the capacity of the library to uncover off-target or novel activities (Am J Cancer Res 2022).

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 unique, clinically approved compounds, each provided as a pre-dissolved 10 mM DMSO solution, enabling direct use in high-throughput or high-content screening platforms (APExBIO).
• Stability studies indicate compound integrity is maintained for 12 months at -20°C and up to 24 months at -80°C (see product datasheet: APExBIO).
• Eltrombopag was identified via ligand screening of this library as a direct binder and functional modulator of syndecan-4, with a dissociation constant (Kd) of ~2 µM in pancreatic cancer cell lines (Can Cui et al., Am J Cancer Res 2022).
• High-throughput screening with the L1021 kit has been validated in cell viability, cytotoxicity, and pathway activation assays across cancer, infectious, and neurodegenerative disease models (B-Pompilidotoxin article).
• Peer-reviewed studies report high reproducibility and low inter-plate variability (<10% CV) when using the DiscoveryProbe™ library in automated screening workflows (Amyloid-A article).

This article extends prior reviews by detailing molecular mechanisms and direct evidence of off-target effects elucidated via the DiscoveryProbe™ FDA-approved Drug Library, as observed in recent cancer cell signaling studies (KNK437 article).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports a spectrum of biomedical research:

• Drug repositioning screening: enables the identification of alternative clinical uses for approved compounds.
• Pharmacological target identification: systematic deconvolution of cellular phenotypes to druggable proteins or pathways.
• Cancer research drug screening: validated in assays for proliferation, invasion, and pathway modulation.
• Neurodegenerative disease drug discovery: supports screening for protein misfolding and chaperone effects (KNK437 article).
• Signal pathway regulation and enzyme inhibitor screening: enables systematic perturbation of canonical pathways.

Common Pitfalls or Misconceptions

• Misconception: The library covers all approved drugs globally.
  Clarification: The set is comprehensive but may not include every regional approval; always verify compound list for jurisdictional coverage.
• Pitfall: Misinterpreting off-target effects as primary mechanism.
  Clarification: Systematic secondary assays are required to confirm on-target activity, as some drugs (e.g., eltrombopag) exhibit unexpected protein interactions (Am J Cancer Res 2022).
• Limitation: Does not include investigational compounds or natural products not yet FDA/EMA/HMA/CFDA/PMDA-approved.
• Pitfall: Overlooking DMSO compatibility with assay systems.
  Clarification: Ensure final DMSO concentrations in the assay are within tolerated limits for cells/enzymes.
• Misconception: The library is only for cancer research.
  Clarification: While broadly used in oncology, it is equally applicable to infectious, metabolic, and neurodegenerative studies.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is delivered as pre-dissolved 10 mM DMSO solutions in multiple formats: 96-well microplates, deep-well plates, or 2D-barcoded screw-cap tubes. Shipping occurs on blue ice for evaluation samples and at room temperature or blue ice for larger sets. Upon arrival, compounds should be stored at -20°C (stable for 12 months) or -80°C (up to 24 months). For screening, recommended dilution protocols maintain DMSO concentrations below 0.5% in final assay mixtures. The library is compatible with automated liquid handlers and robotic systems, facilitating integration into automated HTS and HCS workflows. Compound mapping is provided with digital plate maps and barcoding for traceability.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) by APExBIO remains a benchmark tool for translational drug discovery. Its curated composition, diverse mechanistic coverage, and validated stability make it indispensable for drug repositioning, pharmacological target identification, and mechanistic studies in oncology, neurodegeneration, and beyond. Peer-reviewed evidence underscores its reproducibility and ability to reveal both expected and novel drug–target interactions. Researchers are encouraged to leverage this resource for systematic screening and to validate findings using orthogonal approaches.

For detailed information, compound lists, and purchasing, visit the DiscoveryProbe™ FDA-approved Drug Library product page.